Psychological impact of testing for thrombophilic alterations

Thrombosis and Haemostasis

Volumn 96, Issue 3, 2006, Pages 348-355

  Legnani, Cristina ^a   Razzaboni, Elisabetta ^b   Gremigni, Paola ^b   Bitti, Pio Enrico Ricci ^b   Favaretto, Elisabetta ^a   Palareti, Gualtiero ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Psychological impact; Risk factors; Screening; Thrombophilia

Indexed keywords

ADULT; AGE; AGED; ANTITHROMBIN DEFICIENCY; ANXIETY; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DEPRESSION; DISEASE COURSE; FEAR; FEMALE; GENE MUTATION; HEALTH STATUS; HUMAN; HYPERHOMOCYSTEINEMIA; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; PATIENT COUNSELING; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; PSYCHOMETRY; QUESTIONNAIRE; SCORING SYSTEM; STRESS; THROMBOPHILIA; WELLBEING;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANXIETY; FEMALE; GENETIC COUNSELING; GENETIC SCREENING; GENETIC TESTING; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; MUTATION; QUESTIONNAIRES; RISK FACTORS; THROMBOPHILIA;

EID: 33748597100     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH06-01-0015     Document Type: Article

References (34)

1. Shaw C, Abrams K, Marteau TM. Psychological impact of predicting individuals' risks of illness: a systematic review. Soc Sci Med 1999; 49: 1571-98.
2. Almqvist EW, Bloch M, Brinkman R, et al. A worldwide assessment of the frequency of suicide, suicide attempts, or psychiatric hospitalization after predictive testing for Huntington's disease. Am J Hum Genet 1999; 64: 1293-304.
3. Harper PS, Lim C, Craufurd D. Ten years of pre-symptomatic testing for Huntington's disease: the experience of the UK Huntington's Disease Prediction Consortium. J Med Genet 2000; 137: 567-71.
4. Horowitz MJ, Field NP, Zanko A, et al. Psychological impact of news of genetic risk for Huntington disease. Am J Med Genet 2001; 103: 188-92.
5. Almqvist EW, Brinkmana RR, Wigginsa S, et al. Psychological consequences and predictors of adverse events in the first 5 years after predictive testing for Huntington's disease. Clin Genet 2003; 64: 300-9.
6. Lodder L, Frets PG, Trijsburg RW, et al. Psychological impact of receiving a BRCA1/BRCA2 test result. Am J Med Genet 2001; 98: 15-24.
7. Power TE, Adams PC. Psychosocial impact of C282Y mutation testing for hemochromatosis. Genet Test 2001; 5: 107-10.
8. Marteau TM, Croyle RT. The new genetics. Psychological responses to genetic testing. Br Med J 1998; 316: 693-6.
9. Lodder LN, Frets PG, Trijsburg RW, et al. One year follow-up of women opting for presymptomatic testing for BRCA1 and BRCA2: emotional impact of the test outcome and decisions on risk management (surveillance or prophylactic surgery). Breast Cancer Res Treat 2002; 73: 97-112.
10. Timman R, Stijnen T, Tibben A. Methodology in longitudinal studies on psychological effects of predictive DNA testing: a review. J Med Genet 2004; 41: e100.
11. Legnani C, Palareti G, Guazzaloca G, et al. Venous thromboembolism in young women; role of thrombophilic mutations and oral contraceptive use. Eur Heart J 2002; 23: 984-90.
12. Zotti AM, Bertolotti G, Michielin P, et al. Linee guida per lo screening di tratti di personalitá, cognizioni, e comportamenti avversi alla salute. Manuale d'uso per il CBA Forma Hospital: Edizioni Fondazioni Maugeri, 2000.
13. Sarasin FP, Bounameaux H. Decision analysis model of prolonged oral anticoagulant treatment in factor V Leiden carriers with first episode of deep vein thrombosis. Br Med J 1998; 316: 95-9.
14. Sanson BJ, Simioni P, Tormene D, et al. The incidence of venous thromboembolism in asymptomatic carriers of a deficiency of antithrombin, protein C, or protein S: a prospective cohort study. Blood 1999; 94: 3702-6.
15. Marchetti M, Pistorio A, Barosi G. Extended anticoagulation for prevention of recurrent venous thromboembolism in carriers of factor V Leiden - Cost-effectiveness analysis. Thromb Haemost 2000; 84: 752-7.
16. van den Belt AGM, Hutten BA, Prins MH, et al. Duration of oral anticoagulant treatment in patients with venous thromboembolism and a deficiency of antithrombin, protein C or protein S - A decision analysis. Thromb Haemost 2000; 84: 758-63.
17. Khamashta MA, Cuadrado MJ, Mujic F, et al. The management of thrombosis in the antiphospholipid-antibody syndrome. N Eng] J Med 1995; 332: 993-7.
18. Ray JG, Chan WS. Deep vein thrombosis during pregnancy and the puerperium: a meta-analysis of the period of risk and the leg of presentation. Obstet Gynecol Surv 1999; 54: 265-71.
19. Martinelli I, Mannucci PM, De Stefano V, et al. Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families. Blood 1998; 92: 2353-8.
20. Vossen CY, Conard J, Fontcuberta J, et al. Risk of a first venous thrombotic event in carriers of a familial thrombophilic defect. The European Prospective Cohort on Thrombophilia (EPCOT). J Thromb Haemost 2005; 3: 459-64.
21. Middeldorp S, Henkens CMA, Koopman MMW, et al. The incidence of venous thromboembolism in family members of patients with factor V Leiden mutation and venous thrombosis. Ann Intern Med 1998; 128: 15-20.
22. Tormene D, Simioni P, Prandoni P, et al. The incidence of venous thromboembolism in thrombophilic children: a prospective cohort study. Blood 2002; 100: 2403-5.
23. Ginsberg JS, Greer I, Hirsh J. Use of antithrombotic agents during pregnancy. Chest 2001; 119: 122S-31S.
24. Martinelli I, Legnani C, Bucciarelli P, et al. Risk of pregnancy-related venous thrombosis in carriers of severe inherited thrombophilia. Thromb Haemost 2001; 86: 800-3.
25. Creinin MD, Lisman R, Strickler RC. Screening for factor V Leiden mutation before prescribing combination oral contraceptives. Fertil Steril 1999; 72: 646-51.
26. Schambeck CM, Schwender S, Haubitz I, et al. Selective screening for the factor V Leiden mutation: is it advisable prior to the prescription of oral contraceptives? Thromb Haemost 1997; 78: 1480-3.
27. Hannaford PC, Webb AMC. Evidence-guided prescribing of combined oral contraceptives: consensus statement. Contraception 1996; 54: 125-9.
28. McPherson K. Third generation oral contraception and venous thromboembolism - the published evidence confirms the committee on safety of medicine's concerns. Br Med J 1996; 312: 68-9.
29. Walker ID. Factor V Leiden: should all women be screened prior to commencing the contraceptive pill? Blood Rev 1999; 13: 8-13.
30. Greaves M, Baglin T. Laboratory testing for heritable thrombophilia: Impact on clinical management of thrombotic disease. Br J Haematol 2000; 109: 699-703.
31. Martinelli I. Pros and cons of thrombophilia testing: pros. J Thromb Haemost 2003; 1: 410-1.
32. Machin SJ. Pros and cons of thrombophilia testing: cons. J Thromb Haemost 2003; 1: 412-3.
33. Van Korlaar IM, Vossen CY, Rosendaal FR, et al. Attitudes toward genetic testing for thrombophilia in asymptomatic members of a large family with heritable protein C deficiency. J Thromb Haemost 2005; 3: 2437-44.
34. Broadstock M, Michie S, Marteau TM. Psychological consequences of predictive genetic testing: a systematic review. Eur J Hum Genet 2000; 8: 731-8.